[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy-induced-peripheral-neuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy-induced-peripheral-neuropathy":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,44,68,96,107,125,149,174,198,217,240,260,282,305,325,355,394,417,440,458,482,513,535,561,580],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053317","transcranial-direct-current-stimulation-for-the-treatment-of-chemotherapy-induced-peripheral-neuropathy-in-cancer-survivors-100053317",false,"NCT07673614","Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors","Improving Sensorimotor Function in CIPN: A Randomized, Sham Controlled, Double Blinded, Crossover Mechanistic Trial of Transcranial Direct Current to the Sensorimotor Cortex","Inclusion Criteria:\n\n* 18 to 85 years of age\n* Diagnosis of cancer, stages I-IV\n* Cancer survivor (not currently receiving chemotherapy, radiation, or immunotherapy)\n* Presence of CIPN defined as new, length-dependent numbness, tingling, and\u002For pain that developed with neurotoxic chemotherapy\n* CIPN20 score ≥ 20\n* Able to walk unassisted\n* Proficient in English\n\nExclusion Criteria:\n\n* Known brain metastases\n* Known neurological conditions aside from chemotherapy-induced peripheral neuropathy (CIPN)\n* History of brain or spinal surgery\n* Neuropathy other than CIPN\n* Significant hearing or vision deficits\n* Vestibulopathy\n* Currently receiving chemotherapy, radiation therapy, or immunotherapy\n* Contraindications to transcranial direct current stimulation (tDCS), including recent seizures\n* Presence of metallic objects in the head\n* Presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices)\n* Active scalp dermatological conditions","ALL","18 Years","85 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.",[28,29,30],"Chemotherapy-Induced Peripheral Neuropathy","Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm","NOT_YET_RECRUITING","2026-07-09",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":22},"2026-08-01",{"date":39,"type":22},"2028-02",{"name":41,"class":42},"University of Michigan Rogel Cancer Center","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100645386","randomized-clinical-investigation-of-photobiomodulation-pbm-for-the-management-of-early-peripheral-neuropathy-related-to-medical-oncologic-therapy-100645386","NCT07681921","Randomized Clinical Investigation of Photobiomodulation (PBM) for the Management of Early Peripheral Neuropathy Related to Medical Oncologic Therapy","ENL","Inclusion Criteria:\n\n* All the patients admitted for medical oncological therapy to the day care facility (Hôpital de Jour) are eligible for the protocol.\n* Age 18 years or above\n* Have no documented or observable psychiatric or neurological disorders that might interfere with study participation (e.g., dementia or psychosis)\n* Be able to understand the ICF and study-related questionnaires\n* Signed informed consent\n\nExclusion Criteria:\n\n* severe or unstable cardio-respiratory or musculoskeletal disease\n* Peripheral neuropathy previous to chemotherapy\n* Receiving potentially neurotoxic therapies other than given for cancer treatment\n* Interruption of more than two consecutive laser treatments",{"count":52,"type":22},98,[25],"Chemotherapy-induced peripheral neuropathy (CIPN) is one of the common complications of cancer treatment and involves paresthesia, numbness and\u002For burning pain in distal limbs. This condition has a high health impact because it is associated with psychological distress, fall risk, and poor sleep quality. Furthermore, it impairs patients' daily activities and thereby decreases their quality of life. The overall incidence of CIPN is approximately 68% in the first month after chemotherapy. The available evidence for preventive and therapeutic options for CIPN is limited. Therefore, only symptom management based on pharmacological and\u002For physical therapy is applied with limited success. Photobiomodulation (PBM) has the potential to reduce the development of CIPN in breast cancer patients. PBM uses visible and\u002For (near)-infrared light at a low power produced by laser diodes or light-emitting diodes (LED) to stimulate tissue repair and reduce inflammation and (neuropathic) pain. Additionally, research demonstrated that the use of PBM for three weeks in a curative setting reduces the CIPN symptoms, which is associated with a better QoL. According to the updated WALT 2022 recommendations it is most optimal for neuropathy patients to receive twelve PBM sessions. The aim of this project is to evaluate the role of PBM administered to patients with \" de novo \" early signs of Peripheral neuropathy (PN) that are supposed to be related to ongoing anti-cancer therapy.",[56],"Chemotherapy Induced Peripheral Neuropathy",[58],"photobiomodulation and peripheral neuropathy","2026-07-01",{"date":61,"type":35},"2026-07-02",{"date":63,"type":22},"2026-09-01",{"date":65,"type":22},"2028-12-31",{"name":67,"class":42},"Jules Bordet Institute",{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":43},"100638275","self-applied-tavns-for-cipn-100638275","NCT07596030","Self-applied taVNS for CIPN","Feasibility of Self-Applied Vagus Nerve Stimulation for Chemotherapy Induced Peripheral Neuropathy","Inclusion Criteria:\n\nChemotherapy-induced peripheral neuropathy (CIPN) group:\n\n* Age 18-80 years\n* Prior exposure to platinum or taxane chemotherapy\n* Glove\u002Fstocking dysesthesias ≥3 months that began after neurotoxic chemotherapy\n* Worst CIPN-related pain ≥4\u002F10 over the last week\n\nRegistry Cohort:\n\n* Age 18-80 years\n* Prior exposure to platinum or taxane chemotherapy\n* Denis any current neuropathic symptoms as described above.\n\nExclusion Criteria:\n\nAll participants:\n\n* Unstable cardiac disease\u002F Known arrhythmias\n* Head or neck cancer or metastases\n* Recent ear trauma or active dermatologic disease at the stimulation site\n* \\\u003C2 months since completion of cancer treatment or surgery\n* Metal implants in the head or neck (e.g., cochlear implant)\n* Implanted electronic devices (e.g., pacemaker)\n* Known allergy to tape\u002Fadhesives\n* History of seizure\u002Fepilepsy, intracranial pathology, or skull defect\n* Pregnancy","80 Years",{"count":77,"type":22},36,[25],"The purpose of this study is to determine the feasibility of using a portable device at home to self-administer transcutaneous auricular vagus nerve stimulation (taVNS). This handheld device has two small electrodes that are placed on specific areas of the outer ear. This device delivers a mild electrical stimulation to the vagus nerve through the ear. This study will explore how taVNS may affect symptoms of chemotherapy-induced peripheral neuropathy (CIPN). Participants will be assigned to one of two cohorts based on the presence of chemotherapy-induced peripheral neuropathy (CIPN). Participants with CIPN will be placed in the intervention cohort (n=24) and will complete a 2-week trial of daily self-applied taVNS. Participants without CIPN will be placed in the registry cohort (n=12) and will complete study measurements without receiving the intervention. The registry cohort will not receive the taVNS intervention but will undergo identical physiological assessments at baseline and at a 2 week follow up to control for testing effects and biological variability.",[56],[82,83,84,85],"vagus nerve stimulation","peripheral neuropathy","heart rate variability","transcranial magnetic stimulation","RECRUITING","2026-06-25",{"date":89,"type":35},"2026-06-26",{"date":91,"type":35},"2026-06-02",{"date":93,"type":22},"2027-07",{"name":95,"class":42},"University of Miami",{"id":97,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":26,"conditions":100,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":106,"locationsCount":43},"100644683",{"count":21,"type":22},[25],[28,29,30],"2026-06-24",{"date":103,"type":35},"2026-06-29",{"date":37,"type":22},{"date":39,"type":22},{"name":41,"class":42},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":43},"100621006","a-virtually-delivered-diet-intervention-laso-3-for-the-improvement-of-chemotherapy-induced-peripheral-neuropathy-in-cancer-survivors-post-treatment-100621006","NCT07365007","A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment","Feasibility of a Virtually Delivered LASO-3 Diet Intervention for Chemotherapy-Induced Peripheral Neuropathy in Post-Treatment Cancer Survivors","Inclusion Criteria:\n\n* 18 years or older\n* At least three months since last receiving neurotoxic chemotherapy\n* Self-report moderate (≥ 2\u002F4) numbness and tingling on the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE™) Numbness and Tingling Severity Item in the last week\n* Speak\u002Fread English\n* Have access to the internet\n\nExclusion Criteria:\n\n* Pre-existing peripheral neuropathy from any cause\n* Plan to begin a new prescription of duloxetine (i.e., first-line treatment for CIPN pain) during the study period\n* Are enrolled in symptom management trials that may alter CIPN severity\n* High grade inflammatory disease such as lupus, Crohn's disease, or rheumatoid arthritis\n* Routine nonsteroidal anti-inflammatory drug (NSAID) or steroid supplementation\n* Consuming an average three or more servings of fish per week and\u002For consuming fish oil capsules containing eicosapentaenoic acid (EPA)+ docosahexaenoic acid (DHA) daily or consuming flax oil capsules daily\n* Consuming an average of less than 5 servings of sweets, candy bars, chocolate, doughnuts, cookies, cakes, pie, brownies, ice cream, pastries, or sugar sweetened beverages (e.g., soda or coffee\u002Ftea) per week",{"count":21,"type":22},[25],"This clinical trial studies whether a virtually delivered diet intervention focused on lower added sugar, higher fiber, and higher omega 3 fatty acid (LASO-3) can be used to improve chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors after treatment. Cancer survivors often experience CIPN during and after cancer treatment with neurotoxic chemotherapy. CIPN is characterized by nerve damage from chemotherapy that leads to numbness, tingling, or pain in the hands or feet. However, there are few treatments to manage CIPN. Inflammation contributes to the development of CIPN and dietary patterns that have been demonstrated to improve diet quality and reduce inflammation in cancer survivors may be promising for use as a CIPN management strategy. The LASO-3 diet intervention consists of virtually delivered nutrition education sessions provided by a Registered Dietitian. The sessions focus on three dietary goals, informed by the United States Dietary Guidelines for Americans: 1) lowering added sugar intake to \\\u003C 10% of daily calories, 2) increasing daily fiber intake to ≥ 20 grams, and 3) increasing intake of moderate-high omega-3 seafood to three or more servings weekly or 3300-3400 mg\u002Fday of alpha-linolenic acid (e.g., plant-based sources include canola or flaxseed oil, walnuts, or flaxseed or chia seeds). The Registered Dietitian tailors the sessions to the patient based on information and feedback obtained throughout the sessions. The LASO-3 diet intervention may be an effective way to improve CIPN in cancer survivors after treatment.",[28,29,30],"2026-06-22",{"date":87,"type":35},{"date":121,"type":35},"2026-02-23",{"date":123,"type":22},"2028-03-01",{"name":41,"class":42},{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":17,"minAge":131,"maxAge":75,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100485822","a-novel-limb-cryocompression-system-for-prevention-of-chemotherapy-induced-peripheral-neuropathy---expansion-study-100485822","NCT05606068","A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy - Expansion Study","Inclusion Criteria:\n\n* Age 21- 80 years.\n* Signed informed consent from patient or legal representative\n* Scheduled to receive weekly paclitaxel chemotherapy\n* Patients may receive other chemotherapy drugs alongside taxane e.g. Platinum\u002FHerceptin.\n\nExclusion Criteria:\n\n* Open skin wound or ulcers of the limbs\n* History of Raynaud's phenomenon, peripheral vascular disease, or poorly controlled diabetes\n* Pregnant woman\n* A score of more than 5 in Total Neuropathy Score (TNS) at baseline for cancer patients","21 Years",{"count":133,"type":22},200,[25],"The study conducted on cancer patients is designed to test safety and efficacy of limb hypothermia in cancer patients using the new Paxman Limb Cryocompression System (PLCS). Ultimately this will lead to the development of a therapy regime that will help to prevent chemotherapy-induced neuropathy in cancer patients.",[137],"Chemotherapy-induced Peripheral Neuropathy",[137,139],"Cryocompression","2026-06-17",{"date":118,"type":35},{"date":143,"type":35},"2022-11-11",{"date":145,"type":22},"2026-11",{"name":147,"class":42},"National University Hospital, Singapore",2,{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":17,"minAge":155,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":148},"100594424","light-therapy-for-chemotherapy-induced-peripheral-neuropathy-in-childhood-cancer-survivors-100594424","NCT07019259","Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors","Inclusion Criteria:\n\n* History of childhood cancer (\\\u003C21 years of age at diagnosis)\n* Current age five years or older (due to availability of validated measures for CIPN in this age group)\n* History of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN\n* CIPN as assessed by a trained physical therapist defined as a score of four or higher on the ped-mTNS (for survivors \\\u003C18 years old at evaluation), or the mTNS (for survivors 18 years or older at evaluation)\n\nExclusion Criteria:\n\n* Currently Pregnant or lactating (by patient report, at initiation or at any point of the study)\n* Inability to sit still for at least 15 minutes\n* Diagnosis of neuropathy prior to cancer treatment\n* Active cancer diagnosis or cancerous skin lesion\n* Central nervous system tumor (due to lack of validated measures for CIPN in this population)\n* Cancer lesion or open wound in the area to be treated, or any condition that can potentially be made worse by the correct or incorrect use of the device.","5 Years",{"count":157,"type":22},20,[25],"The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.",[161,162,137],"Cancer","Childhood Cancer",[164],"Survivors of childhood cancer","2026-06-11",{"date":167,"type":35},"2026-06-12",{"date":169,"type":35},"2025-06-30",{"date":171,"type":22},"2027-04",{"name":173,"class":42},"Yale University",{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":43},"100609814","scrambler-therapy-for-chemotherapy-induced-peripheral-neuropathy-100609814","NCT07219472","Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy","A Randomized, Single-Blind, Sham-Controlled Study of Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Adults with CIPN-related pain for at least three months duration, and for which the participant wants intervention\n* At least three months from the last dose of neurotoxic cancer-directed drug\n* No plan (at the time of study enrollment) for additional neurotoxic cancer-directed therapies for at least five months after trial enrollment\n* Pain rated ≥ four out of 10 in severity (0-10 pain scale) during the seven days prior to enrollment\n* \\> six-month life expectancy\n* Able to complete questionnaires by themselves or with assistance\n* Able to provide informed written consent\n* ECOG Performance Status score ≥ two\n\nExclusion Criteria:\n\n* Pregnant or nursing\n* An operational implanted drug delivery system, implanted electronic medical device, life supporting medical device, and\u002For medical monitoring device\n* History of myocardial infarction or ischemic heart disease within six months of trial enrollment\n* History of epilepsy, brain damage resulting in seizure activity, or use of anticonvulsants for seizure\n* Skin conditions such as open sores that will prevent proper application of electrodes\n* Unwillingness or inability to wean and discontinue gabapentin or pregabalin prior to the start of ST\n* History of symptomatic peripheral neuropathy prior to receiving neurotoxic chemotherapy\n* Prior treatment with Scrambler Therapy",{"count":182,"type":22},90,[25],"This research study is for people who have a condition called chemotherapy-induced peripheral neuropathy (CIPN). This condition develops as a result of receiving medication(s) to treat cancer, particularly chemotherapy. CIPN is characterized by pain, numbness, tingling or burning sensations, typically in the hands and feet of people. These symptoms can lead to physical suffering, limited ability to perform daily activities, and low quality of life. One of the ways to treat CIPN is using a device called Scrambler Therapy. Scrambler Therapy was approved by the Food and Drug Administration (FDA) in 2009 as a treatment for CIPN. The treatment involves electrical signals passing through wires attached to parts of the body via adhesive tabs near where symptoms of CIPN are experienced. A standard treatment course consists of 10 daily sessions lasting about one hour each. The purpose of this study is to determine the effect of a 10-day course of Scrambler Therapy on symptoms of chemotherapy-induced peripheral neuropathy, day-to-day activities, overall quality of life, and use of pain medications. Participants will be randomly assigned to one of two groups. One group will receive Scrambler Therapy. The other group will not receive it. Participants will not know which group they were in until after treatment has completed. Participants in the group who did not receive Scrambler Therapy will have the opportunity to receive it after one month. Participants will be in this research study about 12 to 14 months.",[137,186],"CIPN - Chemotherapy-Induced Peripheral Neuropathy",[188],"Scrambler therapy","2026-06-03",{"date":191,"type":35},"2026-06-04",{"date":193,"type":35},"2026-03-27",{"date":195,"type":22},"2027-12",{"name":197,"class":42},"Case Comprehensive Cancer Center",{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":213,"leadSponsor":215,"locationsCount":43},"100638189","early-phase-1-study-of-wenyang-tongbi-formula-in-the-treatment-of-chemotherapy-induced-polyneuropathy-100638189","NCT07626528","Study of Wenyang Tongbi Formula in the Treatment of Chemotherapy-Induced Polyneuropathy","A Multicenter Evidence-Based Clinical Study on the Safety and Efficacy of Wenyang Tongbi Formula in the Treatment of Chemotherapy-Induced Polyneuropathy","Inclusion Criteria:\n\n* Age: Patients aged between 18 and 80 years (inclusive).\n* Life Expectancy: An anticipated survival time of ≥ 3 months.\n* Performance Status \\& Organ Function: A Karnofsky Performance Status (KPS) score ≥ 60 and adequate organ function.\n* Diagnosis: Histopathologically or cytologically confirmed breast cancer or colorectal cancer.\n* Chemotherapy Regimen: Currently undergoing chemotherapy containing taxanes or oxaliplatin.\n* Neurotoxicity Grade: Presence of Grade ≥ 2 peripheral neurotoxicity (according to NCI-CTCAE criteria) induced by chemotherapy.\n* TCM Syndrome Differentiation: Conforming to the \"Yang Deficiency and Collateral Obstruction with Toxin-Stasis Accumulation Pattern\" as defined in the Guidelines for Clinical Research of New Traditional Chinese Medicines.\n\nExclusion Criteria:\n\n* Allergy History: Known hypersensitivity to the active ingredients or excipients of the study drug\u002Fplacebo; history of allergic constitution; or a history of allergies to ≥ 3 substances.\n* Comorbidities: Presence of severe psychiatric disorders; or pre-existing conditions such as diabetic neuropathy, hypothyroidism, renal insufficiency, radiculopathy, Charcot-Marie-Tooth disease, or Guillain-Barré syndrome.\n* Concomitant Medications: Use of Chinese patent medicines or herbal decoctions specifically for CIPN within 30 days prior to enrollment.\n* Compliance: Inability to adhere to the treatment protocol or difficulty in accurately assessing one's own general condition.\n* Pregnancy \\& Lactation: Pregnant or lactating women.",{"count":206,"type":22},144,[208],"EARLY_PHASE1","This clinical trial aims to evaluate the efficacy of Wenyang Tongbi Granules (a patented Traditional Chinese Medicine prescription) in treating chemotherapy-induced peripheral neuropathy (CIPN). The study compares Wenyang Tongbi Granules with mecobalamin tablets, a standard clinical medication, to determine whether the TCM intervention yields superior outcomes in sensory and motor function of the limbs, as well as overall systemic status, among patients presenting with paresthesia and pain during chemotherapy.\n\nMethods: Participants who develop hand-foot paresthesia or pain during chemotherapy will receive either Wenyang Tongbi Granules or mecobalamin tablets daily for a continuous period of 42 days. Evaluations will be conducted on Day 1, Day 21, and Day 42. Outcome measures include the severity and duration of limb paresthesia, as well as changes in TCM-specific syndromes. Additionally, blood samples will be collected to assess variations in serum levels of multiple cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), before and after the intervention.",[137],{"date":191,"type":35},{"date":59,"type":22},{"date":214,"type":22},"2028-11-01",{"name":216,"class":42},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":224,"minAge":18,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":239},"100526800","cryocompression-to-reduce-chemotherapy-induced-peripheral-neuropathy-in-gynecologic-cancer---cohort-2-100526800","NCT06139458","Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2","Use of Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer: a Randomized Controlled Trial - COHORT 2","Inclusion Criteria:\n\n* Gynecologic cancer diagnosis (ovarian, cervical, endometrial cancer; adenocarcinomas of likely primary gynecologic origin based on cytology or FNA in conjunction with radiologic impression will be eligible)\n* Plan to receive at least 6 cycles of paclitaxel administered every 3 weeks at the Duke Cancer Center or Macon Pond or at the Carilion Clinic in Roanoke, VA. Patients receiving neoadjuvant chemotherapy with a plan for interval debulking will be eligible.\n* ECOG (Eastern Cooperative Oncology Group) performance status of 0-1\n\nExclusion Criteria:\n\n* Treated with prior neurotoxic chemotherapeutic agents\n* Baseline diagnosis of peripheral neuropathy such as diabetic neuropathy, or conditions including but not limited to fibromyalgia, cryoglobulinemia and Raynaud's disease.","FEMALE",{"count":226,"type":22},190,[25],"The investigators aim to determine the effect of cryotherapy wraps plus compression therapy (henceforth referred to as cryocompression) versus cryotherapy wraps alone on the incidence and degree of chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer using a noninferiority design. The investigators also aim to determine the effect of cryocompression versus cryotherapy on patient tolerability and patient and staff satisfaction.",[230,137],"Gynecologic Cancer","2026-06-01",{"date":91,"type":35},{"date":234,"type":35},"2024-01-18",{"date":236,"type":22},"2027-05-31",{"name":238,"class":42},"Duke University",4,{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":248,"phases":4,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":43},"100546037","understanding-and-preventing-cortical-mechanisms-of-chemotherapy-induced-peripheral-neuropathy-100546037","NCT06389721","Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy","Inclusion criteria:\n\nObjective 1 Inclusion criteria\n\n1. Participants must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements.\n2. ECOG Performance Status of 0-2;\n3. Willing to come to MD Anderson for the imaging sessions.\n4. Are 18 years of age or above.\n5. Have a diagnosis of breast cancer.\n6. will receive chemotherapy including doxorubicin, cyclophosphamide, docetaxel, or paclitaxel;\n\nObjective 2 Inclusion criteria:\n\n1\\) Inclusion criteria: Identical to Objective 1 and are willing to participate in the therapy sessions at their homes.\n\nExclusion Criteria\n\nObjective 1 Exclusion criteria:\n\n1. Participants who are taking any antipsychotic medications.\n2. With active CNS disease, such as clinically evident metastases or leptomeningeal disease, dementia, or encephalopathy.\n3. Have ever been diagnosed with bipolar disorder or schizophrenia.\n4. Known, previously diagnosed peripheral neuropathy from any causes and\n5. A history of head injury or who have known seizure activity.\n\nObjective 2 Exclusion criteria\n\n1\\) Same exclusion criteria as in Objective1. Medication usage will be tracked for patients in all groups. Once prescribed, participants must remain on a stable course of medications throughout the course of chemotherapy.",{"count":247,"type":22},45,"OBSERVATIONAL","Cohort 1: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN).\n\nCohort 2: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN) and to test a certain type of experimental neuromodulation (stimulation of the brain) with a device called a closed-loop brain-computer interface (clBCI) to see if can help to prevent pain due to CIPN.",[137],"2026-05-15",{"date":253,"type":35},"2026-05-19",{"date":255,"type":35},"2024-07-16",{"date":257,"type":22},"2027-01-31",{"name":259,"class":42},"M.D. Anderson Cancer Center",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":23,"phases":269,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":43},"100594248","phase-1-cbgcbd-oil-for-chemotherapy-induced-peripheral-neuropathy-100594248","NCT07016971","CBG\u002FCBD Oil for Chemotherapy-Induced Peripheral Neuropathy","A Pilot Study to Evaluate the Feasibility, Safety, and Efficacy of Cannabigerol\u002FCannabidiol Oil for Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Adults aged 21 years or older.\n* Patients with grade 1 or greater CIPN symptoms, such as neuropathic pain, paresthesia, or muscle weakness, persisting for more than 2 weeks as defined by the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 5.\n* Patients who have completed platinum-based chemotherapy for colorectal carcinoma, biliary tract carcinoma, pancreatic carcinoma, esophageal carcinoma, gastric carcinoma, or small intestinal carcinoma within the past 2 years.\n* Patients currently taking any treatment for CIPN must discontinue such treatments at least 2 weeks prior to enrollment.\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (A pregnancy teste will be performed during screening (up to 28 days before treatment and repeated within 7 days prior to study drug initiation to confirm baseline status and minimize risk of unrecognized pregnancy).\n* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 1 months after the last dose of protocol therapy. Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only).\n* Patients from Penn State Health.\n\nExclusion Criteria:\n\n* Patients under the age of 21 years.\n* Patients with a history of preexisting neuropathy prior to chemotherapy.\n* Pregnant and nursing women.\n* Patients with hypertension that, in the investigator's judgement, is uncontrolled despite the use of anti-hypertensives, or with hypotension (systolic blood pressure \\\u003C90 mmHg and\u002For diastolic blood pressure \\\u003C60 mmHg).\n* History of or active arterial thromboembolic event (e.g. stroke, myocardial infarction).\n* Patients who have used an investigational drug within 30 days prior to the screening visit or are currently participating in another interventional investigational study.\n* Patients who have liver function tests AST\u002FALT \\> 3 times above the upper limits of normal (ULN) in the past year.\n* Patients who have suicidal ideation or uncontrolled depression within the past year.\n* Patients with known sensitivity to any components of CBG\u002FCBD hemp extract.\n* Patients with known sensitivity to coconut oil.\n* Patients currently receiving active systemic anti-cancer therapies, including but not limited to chemotherapy, immunotherapy, targeted therapy (e.g., tyrosine kinase inhibitors, anti-HER2 therapy), or any other ongoing systemic treatment intended to control or reduce tumor burden.\n* Current use of moderate or strong inhibitors or inducers of CYP3A4 or CYP2C19.\n* Current use of sensitive CYP2C19 substrates with narrow therapeutic indices (e.g., diazepam, clobazam), unless the subject's primary physician agrees to adjust the dose and provide close therapeutic monitoring.\n* Current use of valproate or other medications known to significantly increase the risk of liver enzyme elevations when co-administered with cannabidiol.\n* Current use of medications that are primarily metabolized by CYP1A2 (e.g., theophylline) or CYP2B6 (e.g., bupropion, efavirenz) that cannot be safely monitored or dose-adjusted per the discretion of the study investigator. Occasional or dietary caffeine intake is permitted.\n* Current use of medications that are substrates of UGT1A9 (e.g., diflunisal, propofol, fenofibrate), UGT2B7 (e.g., gemfibrozil, lamotrigine, morphine, lorazepam), CYP2C8, or CYP2C9 (e.g., phenytoin) that cannot be safely monitored or dose-adjusted per the discretion of the study investigator.\n* Current use of other known hepatotoxic drugs unless the potential risk has been evaluated and deemed acceptable by the study investigator.",{"count":268,"type":22},12,[270],"PHASE1","The goal of this clinical trial is to learn if a commercially available cannabigerol (CBG)\u002Fcannabidiol (CBD) oil is safe, feasible to use, and can help reduce symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in adults who have completed platinum-based chemotherapy for gastrointestinal cancers. The main questions it aims to answer are:\n\nIs CBG\u002FCBD oil safe and well-tolerated over a 12-week treatment period?\n\nCan participants with CIPN use CBG\u002FCBD oil consistently as part of their care?\n\nDoes CBG\u002FCBD oil help reduce pain, numbness, or other symptoms of CIPN?\n\nParticipants will:\n\nTake CBG\u002FCBD oil under the tongue (sublingually) twice daily for 12 weeks\n\nComplete regular symptom assessments and functional tests during study visits\n\nProvide blood samples for cannabinoid and metabolite level testing",[28],"2026-05-06",{"date":275,"type":35},"2026-05-11",{"date":277,"type":35},"2026-04-03",{"date":279,"type":22},"2029-07-03",{"name":281,"class":42},"Milton S. Hershey Medical Center",{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":4},"100636959","a-single-arm-prospective-study-of-papaverine-for-the-treatment-of-refractory-peripheral-neuropathy-induced-by-taxane-based-chemotherapy-100636959","NCT07572461","A Single-Arm, Prospective Study of Papaverine for the Treatment of Refractory Peripheral Neuropathy Induced by Taxane-Based Chemotherapy","Inclusion Criteria:\n\n* Age 18 to 75 years.\n* Histologically or cytologically confirmed malignancy.\n* Prior treatment with a taxane-containing chemotherapy regimen, including but not limited to paclitaxel, docetaxel, or nab-paclitaxel, with completion of chemotherapy at least 4 weeks before enrollment.\n* Persistent, clinically significant peripheral neuropathy mainly attributed to taxane-based chemotherapy, with NCI-CTCAE v5.0 sensory neuropathy grade ≥ 2.\n* Failure of at least one standard treatment for chemotherapy-induced peripheral neuropathy, such as duloxetine ≥ 60 mg\u002Fday, pregabalin ≥ 150 mg\u002Fday, or gabapentin ≥ 900 mg\u002Fday, for at least 4 weeks, defined as lack of symptom improvement or intolerance to treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Adequate organ function, including hematologic, hepatic, and renal function within acceptable ranges.\n* Willingness to participate and ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Peripheral neuropathy due to causes other than chemotherapy, such as uncontrolled diabetes mellitus (HbA1c \\> 7.0%), severe renal insufficiency, vitamin B12 deficiency, thyroid dysfunction, or history of alcohol abuse.\n* Known hypersensitivity to papaverine or any of its components.\n* Contraindications to papaverine, such as complete atrioventricular block.\n* Current use of other investigational drugs that may affect neurological function.\n* Pregnant or breastfeeding women.\n* Severe hepatic or renal dysfunction, defined as ALT or AST \\> 3 × upper limit of normal or serum creatinine \\> 2 × upper limit of normal.\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.","75 Years",{"count":290,"type":22},43,[25],"Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often long-lasting side effect of cancer treatment. Patients may experience numbness, tingling, pain, burning sensations, weakness, or difficulty with walking and daily activities. Paclitaxel-related CIPN is especially common, and current treatment options are limited. For patients whose symptoms do not improve with standard therapies such as duloxetine, pregabalin, or gabapentin, there is an important unmet clinical need. Papaverine is a vasodilator and smooth muscle relaxant that may improve blood flow in the small vessels supplying nerves. Based on the hypothesis that impaired microcirculation and ischemia may contribute to CIPN, papaverine may help relieve symptoms and support nerve recovery. Preliminary clinical observations by the investigators suggested that papaverine injection may rapidly improve numbness and weakness in some patients with refractory paclitaxel-induced CIPN.This is a prospective, single-center, single-arm, open-label phase II study designed to evaluate the preliminary efficacy and safety of papaverine injection in patients with refractory paclitaxel-induced peripheral neuropathy. Eligible participants are adults aged 18 to 75 years with histologically or cytologically confirmed malignancy, prior treatment with a paclitaxel-containing regimen, persistent clinically significant neuropathy of grade 2 or higher, and failure of at least one standard treatment for CIPN. Participants will receive papaverine hydrochloride 120 mg diluted in 100 mL normal saline by intravenous infusion once daily, given as 1 treatment day followed by 6 rest days, with 7 days defined as one cycle. Up to 3 cycles of treatment may be given if patients benefit and tolerate therapy well.The main goal of the study is to assess improvement in patient-reported sensory neuropathy symptoms using the EORTC QLQ-CIPN20 sensory subscale. Secondary objectives include changes in overall neuropathy symptoms, physician-assessed neuropathy grade, quality of life, and safety. Exploratory assessments include nerve conduction findings and inflammatory biomarkers. The study aims to enroll approximately 43 patients and will provide early evidence on whether papaverine may be a useful treatment option for patients with refractory paclitaxel-induced CIPN.",[28,294,295],"Refractory Chemotherapy-Induced Peripheral Neuropathy","Paclitaxel-Induced Peripheral Neuropathy","2026-05-05",{"date":298,"type":35},"2026-05-07",{"date":300,"type":22},"2026-05-01",{"date":302,"type":22},"2027-05-01",{"name":304,"class":42},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":312,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":43},"100588744","evaluating-a-mobile-health-application-intervention-for-caregiver-instruction-in-manual-therapy-for-chemotherapy-induced-peripheral-neuropathy-100588744","NCT06945380","Evaluating a Mobile Health Application Intervention for Caregiver Instruction in Manual Therapy for Chemotherapy-Induced Peripheral Neuropathy","mHealth App for Caregiver Instruction in Manual Therapy for Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* 18+ years of age.\n* Must speak and read English.\n* Have internet access.\n* PATIENTS: Must have received neurotoxic chemotherapy for adjuvant treatment of cancer.\n* PATIENTS: Screens positive for moderate to severe CIPN with a 4+ on a 0-10 scale, with 0 being no numbness\u002Ftingling or pain in hands or feet and 10 being most severe imaginable.\n* PATIENTS: Last chemo dose must be 6+ months in the past (symptoms persist in 30% of recipients \\> 6 months, this assures those with established chronicity are included, reducing likelihood of spontaneous improvement). Also, no new chemotherapy should be anticipated during the study course.\n* PATIENTS: Must have internet access.\n* CAREGIVERS: Members of the patient's natural social support system including spouse, intimate partner, other family member (adult child, parent, other relative), friend or other lay person designated by the patient who agrees to serve as caregiver for the activities of the project.\n\nExclusion Criteria:\n\n* PATIENTS: Other potential cause of neuropathy (e.g., diabetes).\n* PATIENTS: Ongoing treatment with a neuropathy-causing medication.\n* PATIENTS: History of oncology massage therapy for neuropathy in the last 3 months.\n* PATIENTS: Unstable lymphedema-if the patient is considered at risk of lymphedema, they can participate because level 2 pressure is deemed safe; however, if patient has had lymphedema, their condition must be declared stable by a certified lymphedema therapist (if stable, level 2 pressure is safe for this study's interventions).",true,{"count":314,"type":22},300,[25],"This clinical trial assesses the impact of a family caregiver-delivered massage technique for use in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a common cancer treatment side effect that impairs quality of life and daily functioning. Aside from the relatively transient effects of chemotherapy treatment (e.g., nausea, diarrhea, vomiting, infections, fatigue, hair loss), chemotherapy can damage nervous system structures leading to long-term CIPN effects including numbness in hands or feet, \"pins and needles\" or sudden stabbing pains, difficulty buttoning clothing or picking up objects, loss of balance and risk of falling, difficulty driving (steering wheel, foot pedals), and increased sensitivity to heat or cold. Caregivers who lack effective strategies of supportive care are at risk of feeling helpless, overwhelmed or frustrated watching their loved one suffer. Oncology massage (OM) teaches oncology-informed modifications, adaptations and safety precautions for a cancer survivor's specific condition, treatment history and side effects. An mobile health application (app) for caregivers can teach care for CIPN using safe oncology-informed massage techniques at home. Using the Peripheral Neuropathy Relief (PNR) program in the form of relaxation may help for stress reduction, reduced CIPN symptoms, and\u002For an increased sense of connection with patients and their family caregiver.",[28,30,29],{"date":273,"type":35},{"date":320,"type":35},"2025-05-27",{"date":322,"type":22},"2026-05-31",{"name":324,"class":42},"Mayo Clinic",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":312,"sex":17,"minAge":18,"maxAge":288,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":335,"conditions":336,"keywords":337,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":43},"100394425","the-role-of-trp-channels-in-cipn-100394425","NCT04415892","The Role of TRP Channels in CIPN","The Role of Transient Receptor Potential Channels in Chemotherapy-Induced Peripheral Neuropathic Pain.","Inclusion Criteria Healthy volunteers:\n\n1. Subject is a white male ≥18 and ≤45 years of age.\n2. Subject is a non-smoker for at least 6 months prior to the start of the study.\n3. Subject has a body mass index between 18-30 kg\u002Fm².\n4. Subject is judged to be in good health on the basis of medical history, physical examination and vital signs.\n5. Subject understands the procedures and agrees to participate in the study by giving written informed consent.\n6. Subject is matched to the patient groups for sex, age and BMI (only part II).\n\nInclusion Criteria Patients of Part II:\n\n1. Subject is a white male or female ≥18 and ≤70 years of age.\n2. Subject is a non-smoker for at least 6 months prior to the start of the study.\n3. Subject has a BMI between 18-35 kg\u002Fm².\n4. Subject has a history of treatment with one of the following chemotherapeutic agents:\n\n   * Paclitaxel\n   * Oxaliplatin\n5. Subject suffers from peripheral neuropathy grade 1, 2 or 3 according to the Total Neuropathy Score (clinical version). Grade 1 correlates to a score of 1-7, grade 2 to a score of 8-14 and grade 3 to a score of 15-21(10-12).\n6. Subject suffers from neuropathic symptoms in the upper limbs.\n7. Discontinuation or termination of therapy with the chemotherapeutic agent occurred \\>1 month and \\\u003C 1 year ago.\n8. Subject understands the procedures and agrees to participate in the study by giving written informed consent.\n\nInclusion Criteria for patients of Part III\n\n1. Subject is a white male or female ≥18 and ≤75 years of age.\n2. Subject is a non-smoker for at least 6 months prior to the start of the study.\n3. Subject has a BMI between 18-35 kg\u002Fm².\n4. Subject will receive treatment with paclitaxel or oxaliplatin in the near future.\n5. Subject understands the procedures and agrees to participate in the study by giving written informed consent.\n\nExclusion Criteria:\n\n1. Subject has eczema, scleroderma, psoriasis, dermatitis, or keloids, tumors, ulcers, burns, flaps or grafts on their fingers or any other abnormality of the skin which, in the opinion of the investigator may interfere with the study assessments.\n2. Subject has excessive hair growth on the fingers.\n3. Subject cannot avoid excessive tanning (any exposure to sunlight or a tanning bed which would cause a sunburn reaction) throughout the study.\n4. Subject has a history of significant severe (drug) allergies.\n5. Subject uses any prescription or non-prescription drugs on a regular basis which, in the investigator's opinion, might confound the results of the study.\n6. Subject currently uses lotions, oils, depilatory preparations, makeup, or other topical treatments on the fingers on a regular basis which cannot be discontinued for the duration of the study.\n7. Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, is currently a regular user of any illicit drugs, or has a history of drug (including alcohol) abuse.\n8. Subject is unable to refrain from drinking caffeinated beverages (e.g. coffee, tea, cola, …) 24 hours prior to each study visit. Subject is unable to limit their intake of caffeinated beverages to ≤4 cups a day throughout the study.\n9. Subject has any of the following vital sign measurements at screening after at least 10 minutes of supine rest: Heart Rate \\\u003C40 or \\>100 beats\u002Fmin, Diastolic Blood Pressure \\\u003C50 or \\>90 mmHg, Systolic Blood Pressure \\\u003C90 or \\>140 mmHg.\n10. Subject is currently participating or has been involved in testing an investigational drug in another clinical study within the last 4 weeks.\n11. Subject is in a situation or has a condition which, in the opinion of the investigator, may interfere with safe and optimal participation in the study.\n12. Subject has a history of any illness or disorder which, in the investigator's opinion, might confound the results of the study.\n13. Subject suffered from peripheral neuropathy prior to the chemotherapeutic treatment (Only for patients).\n14. Subject has (a history of) diabetes mellitus, amyloidosis, vitamin B deficiency or any other medical disorder that, in the investigator's opinion, may cause peripheral neuropathy (only for Part II and III).\n15. Subject has (a history of) a lesion in the central nervous system that is known to possibly cause neuropathic pain: e.g. spinal cord injury, infarction localized in the brainstem or thalamus, syringomyelia, multiple sclerosis, or any other disorder of the CNS that, in the investigator's opinion, may cause neuropathic pain (only for Part II and III).\n16. Subject has a history of treatment with bortezomib, vincristine, or any other compound that, in the investigator's opinion, may cause neuropathic pain (only for Part II and III).\n17. Subject did not develop neuropathy after treatment with epirubicine-cyclofosfamide (only for the paclitaxel group in Part III).\n18. Subject has a family history of peripheral neuropathy (only for Part II and III).",{"count":333,"type":22},240,[25],"Part I:\n\nEvaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in healthy, male volunteers. In addition, the inter-period and inter-hand reproducibility of the increase in dermal blood flow will be assessed.\n\nPart II:\n\nEvaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in patients suffering from chemotherapy-induced peripheral neuropathy compared to matched healthy volunteers.\n\nPart III:\n\nEvaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in patients who are treated with paclitaxel or oxaliplatin.",[137],[338,339,340,341,342,343,344,345,346],"Cinnamaldehyde","Capsaicin","Dermal Blood Flow","Fingers","Human","Reproducibility","Paclitaxel","Oxaliplatin","Peripheral Neuropathy","2026-04-28",{"date":296,"type":35},{"date":350,"type":35},"2019-10-01",{"date":352,"type":22},"2026-12-01",{"name":354,"class":42},"Universitaire Ziekenhuizen KU Leuven",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":373,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":43},"100635881","extracellular-vesicles-and-chemotherapy-induced-peripheral-neuropathy-100635881","NCT07558447","Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy","Extracellular Vesicles as Predictive Biomarkers for Chemotherapy-Induced Peripheral Neuropathy","CHEMOVES","Inclusion Criteria:\n\n* Has signed the informed consent form\n* Is 18 years of age or older\n* Is male or female\n* Has breast cancer and is scheduled to receive paclitaxel, docetaxel, eribulin, capecitabine, or carboplatin as part of standard care\n* Has gastrointestinal cancer and is scheduled to receive oxaliplatin or capecitabine as part of standard care\n* Has lung cancer and is scheduled to receive cisplatin, carboplatin, or docetaxel as part of standard care\n* Has urologic cancer and is scheduled to receive carboplatin, cisplatin, paclitaxel, docetaxel, or enfortumab vedotin as part of standard care\n* Has head and neck cancer and is scheduled to receive carboplatin, paclitaxel, or cisplatin as part of standard care\n\nExclusion Criteria:\n\n* Has already been diagnosed with CIPN\n* Has a neurodegenerative disease",{"count":364,"type":22},120,[25],"The goal of this clinical trial is to learn whether extracellular vesicles (EVs) in the blood can be used as biomarkers to predict chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer patients receiving chemotherapy with taxanes, platinum compounds, or antimitotic drugs. The main questions the study aims to answer are whether blood levels of EVs change in patients who develop CIPN during and after chemotherapy and whether specific features of EVs, including lipids and microRNAs, are associated with the development and severity of CIPN. Participants will be followed from before the start of chemotherapy until six months after treatment ends to evaluate how changes in EVs relate to nerve damage caused by chemotherapy. During the study, participants will provide blood samples before chemotherapy, at the end of treatment, and six months later for measurement and molecular analysis of EVs, will complete questionnaires about neuropathy symptoms, and will undergo simple, non-invasive nerve function tests using a tuning fork (diapason) and a Neuropen device. This study does not test cancer drugs; instead, it aims to identify biological markers in blood that may help predict which patients are at higher risk of developing CIPN, with the goal of improving monitoring and care during cancer treatment.",[28,368,369,370,371,372],"Breast Cancer","Gastrointestinal Cancer","Lung Cancer","Urologic Cancer","Head and Neck Cancer",[28,374,375,376,377,344,378,379,380,381,345,382,383,384,161],"Neurotoxicity","Extracellular Vesicles","Biomarkers","Liquid Biopsy","Docetaxel","Eribulin","Capecitabine","Carboplatin","Cisplatin","Enfortumab Vedotin","Neuropathy","2026-04-23",{"date":387,"type":35},"2026-04-30",{"date":389,"type":35},"2025-01-01",{"date":391,"type":22},"2026-09",{"name":393,"class":42},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":288,"enrollmentInfo":401,"targetDuration":4,"studyType":23,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":4},"100635767","exercise-and-mindfulness-intervention-for-chemotherapy-induced-peripheral-neuropathy-in-patients-with-cancer-100635767","NCT07556965","Exercise and Mindfulness Intervention for Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer","Effect of an Exercise- and Mindfulness-Based Cognitive Therapy Intervention on Physical and Psychological Symptoms in Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Patients with a pathologically confirmed malignant tumor;\n* Currently receiving neurotoxic chemotherapy and experiencing chemotherapy-induced peripheral neuropathy (CIPN);\n* Cancer stage Tis or stage I-III;\n* Aged 18 years or older, with normal consciousness, mental status, and verbal communication ability; able to understand and judge their own sensations and general condition; and able to complete the questionnaires;\n* Willing to participate in the study and able to provide written informed consent;\n* Patients with NCI-CTCAE grade \\\u003C2 who are considered suitable for exercise intervention.\n\nExclusion Criteria:\n\n* Presence of other neurological diseases or severe psychiatric disorders;\n* Presence of other serious illnesses, such as severe heart disease or respiratory failure;\n* Inability to understand or complete the questionnaires;\n* Participation in psychological counseling, psychotherapy, or other clinical trials within the past 6 months;\n* Inability or expected inability to complete the full 6-week intervention.",{"count":402,"type":22},40,[25],"The goal of this clinical trial is to learn whether an exercise- and mindfulness-based cognitive therapy intervention can improve physical and psychological symptoms in cancer patients with chemotherapy-induced peripheral neuropathy. It will also examine whether this intervention can improve quality of life. The main questions it aims to answer are:\n\nCan this intervention reduce physical symptoms related to chemotherapy-induced peripheral neuropathy? Can this intervention reduce psychological symptoms in affected patients? Can this intervention improve patients' quality of life?\n\nParticipants will:\n\nFollow a structured program of regular exercise and mindfulness practice Undergo weekly assessments of symptom changes Keep records of their symptom changes during the intervention period",[406,28,407],"Cancer Patients","Exercise Intervention","2026-04-22",{"date":410,"type":35},"2026-04-29",{"date":412,"type":22},"2026-04-20",{"date":414,"type":22},"2027-06-30",{"name":416,"class":42},"Nanjing Medical University",{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":426,"conditions":427,"keywords":429,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":43},"100597923","cryocompression-for-cipn-100597923","NCT07064798","Cryocompression for CIPN","Evaluating the Use of Limb Cryocompression to Reduce Taxane-induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Adults \\> 18 years of age\n* Gynecologic or breast malignancy\n* Starting 1st cycle of treatment with chemotherapy regimens:\n\n  * Weekly paclitaxel x 12 or weekly paclitaxel\u002Fcarboplatin x 12, Q2 weeks paclitaxel X4 (preceded by doxorubicin\u002Fcyclophosphamide). (Breast Oncology)\n  * Q3 weeks paclitaxel\u002Fcarboplatin X 6-8 (GYN)\n* Receiving treatment on the main campus of DFCI (these patients are currently seen on Yawkey 9 and 10 and at Chestnut Hill)\n* Able to complete questionnaires in English or Spanish\n\nExclusion Criteria:\n\n* Previous exposure to neurotoxic chemotherapy\n* Pre-existing neuropathy\n* History of Raynaud's phenomenon, cold agglutinin disease, cryoglobulinemia, cryofibrinogenemia, post-traumatic cold dystrophy, peripheral arterial ischemia, or sickle cell disease\n* Undergoing desensitization\n* Lymphedema in the limb where the device would be applied\n* Open skin wounds or ulcers of the limbs where the device would be applied",{"count":21,"type":22},[25],"This study aims to evaluate the effectiveness, tolerability, and safety of using cooling therapy and pressure (cryocompression) to reduce peripheral neuropathy, a condition affecting the nerves supplying the arms and legs (limbs) resulting in possible numbness, pain, and\u002For loss of motor function, that may occur as a result of taxane-based chemotherapy.\n\nThe name of the device used in this research study is:\n\n-Paxman Limb Cryocompression System (PLCS)",[137,428,186],"Taxane-Induced Peripheral Neuropathy",[346,137,428,430],"CIPN","2026-04-14",{"date":433,"type":35},"2026-04-15",{"date":435,"type":35},"2025-10-22",{"date":437,"type":22},"2027-08",{"name":439,"class":42},"Dana-Farber Cancer Institute",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":312,"sex":17,"minAge":447,"maxAge":18,"enrollmentInfo":448,"targetDuration":4,"studyType":248,"phases":4,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":456,"locationsCount":43},"100422910","physiologic-measure-of-vipn-100422910","NCT04786977","Physiologic Measure of VIPN","Development of a Physiologic Measure of Vincristine Induced Peripheral Neuropathy in Children and Adolescents","Inclusion Criteria:\n\n* 6-18 years of age at the start of the study, are receiving vincristine in DI (clinical study population) and are willing and able to provide informed consent or assent to study participation.\n\nExclusion Criteria:\n\n* have eye pathology which precludes pupillometry, are hemodynamically unstable, or are pregnant.","6 Years",{"count":402,"type":22},"The purpose of this study is the development of a physiologic endpoint using a novel technology that would provide an objective, easy to use and more sensitive assessment of VIPN in children and adolescents. The ability to more easily detect and monitor VIPN, even before it is clinically evident, would facilitate optimizing the dosing of vincristine for maximal disease response while minimizing the risk of lifelong functional deficits affecting quality of life. This approach would also enable the development of specific therapies to minimize or eliminate the occurrence of VIPN in children and adolescents. This is a single site study that aims to develop a novel device to evaluate and characterize vincristine-induced neuropathic pain. The investigators will enroll patients with ALL following the Delayed Intensification (DI) phase of treatment. At each study visit, the investigators will evaluate the nPRD as well as the TNS-PV. The nPRD will inform the neuropathy index which will be used to compare to the TNS-PV. We anticipate a correlation between the two.",[137],{"date":452,"type":35},"2026-04-06",{"date":454,"type":35},"2021-09-20",{"date":302,"type":22},{"name":457,"class":42},"Children's National Research Institute",{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":23,"phases":468,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":481},"100503845","phase-3-capsaicin-179-mg-patch-versus-oral-duloxetine-in-patients-with-chemotherapy-induced-peripheral-neuropathy-100503845","NCT05840562","Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy","Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy : a Phase 3 Randomized Multicentric Open-label Study.","CAPNEUCHIM","Inclusion Criteria:\n\n* Patient with CIPN manifested by painful symptoms such as numbness and \u002F or tingling and \u002F or burning pain in fingers \u002F hands and toes \u002F feet with a typical distribution in \"gloves and socks\" beginning after neurotoxic chemotherapy\n* Painful CIPN as expressed by the BPI-SF (average pain) as ≥ 4\u002F10\n* CIPN persisting at least 1 month after completion of chemotherapy with taxanes and\u002For platinum salts and sensory CIPN grade ≥ 2 according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE v.5.0) grading scale\n* Stable doses in the 4 weeks before screening, of concomitant neuropathic pain medication (antiepileptic drugs)\n* Healthy and non-irritated skin on the areas to be treated\n* Absence of neurotoxic chemotherapy planned during the next 6 months after inclusion\n* Patient affiliated to a social security scheme\n* \\> 18 years old\n* Signed written informed consent form\n\nExclusion Criteria:\n\n* Presence of known carcinomatous meningitis\n* Pre-existing known peripheral neuropathy of another aetiology (alcohol, diabetes, …)\n* Hypersensitivity to Capsaicin or contra-indications to duloxetine (e.g imatinib, tamoxifen)\n* Patient already treated for this neuropathy with Capsaicin patches\n* Patient treated by antidepressant drugs at time of inclusion\n* Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 90 mmHg) or recent history (\\\u003C3 months) of cardiovascular events (stroke, heart attack, pulmonary embolism)\n* Patients with known severe renal or hepatic failure\n* Breastfeeding or pregnant women\n* Persons deprived of liberty or guardianship (including curatorship)\n* Patient unable to undergo regular medical follow-up for geographical, social or psychological.",{"count":467,"type":22},274,[469],"PHASE3","Chemotherapy induced peripheral neuropathy (CIPN) is a frequent and disabling complication of systemic chemotherapy, particularly with oxaliplatin or taxanes. The incidence of CIPN is variable but approximately 30-40% of patients treated with neurotoxic chemotherapy agents develop CIPN after long-term use of taxanes or oxaliplatin.\n\nThis CIPN is essentially a sensory peripheral neuropathy with pain manifested by unpleasant symptoms such as numbness, tingling, and less frequently shooting\u002Fburning pain. These symptoms spread proximally to affect both lower and upper extremities in a characteristic \"stocking and glove\" distribution.\n\nMany symptoms of CIPN may resolve completely for some patients. However, CIPN is only partly reversible for most. In the worst instances, it does not appear to be reversible at all and can even increase over time.\n\nCIPN is difficult to manage. Only duloxetine is recommended, based on the positive result of a randomized phase III double-blind placebo-controlled crossover trial. The use of duloxetine resulted in a greater reduction in pain and was effective in decreasing numbness and tingling in the feet. But, systemic antidepressants are often associated with toxicities and patients often refuse or abandon the treatment.\n\nCapsaicin inhibits neural transmission in sensory axons and has been proven as effective on the intensity of pain for post-herpetic neuralgia and human immunodeficiency virus-associated neuropathy. Efficacy appears at one month and persists for at least 2 months.\n\nOnly a few studies focused on the efficacy of capsaicin 179 mg patch on the intensity of CIPN-induced pain. These non-randomized studies show that more than 50% of patients have a reduction in pain intensity of more than 30%.\n\nUntil now, no clinical trial has compared the efficacy of the capsaicin 179 mg patch with duloxetine.\n\nAccordingly, this open-label phase 3, randomized, multicenter trial, will compare efficacy and safety of capsaicin patch with oral duloxetine on painful CIPN persisting more than 3 months after the end of the responsible chemotherapy.",[137],"2026-03-26",{"date":474,"type":35},"2026-03-31",{"date":476,"type":35},"2023-10-20",{"date":478,"type":22},"2028-03",{"name":480,"class":42},"Institut Cancerologie de l'Ouest",11,{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":489,"targetDuration":4,"studyType":23,"phases":491,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":43},"100598513","phase-2-analgesic-efficacy-and-safety-of-topical-vmd-3866-gel-in-management-of-pain-induced-by-chemotherapy-cipn-100598513","NCT07072468","Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)","A Randomized, Double-blind, Placebo-controlled Crossover Study to Evaluate Analgesic Efficacy, Safety and Tolerability of Repeated Doses of Topical VMD-3866 in Patients With Chemotherapy-induced Peripheral Neuropathy (CIPN)","Inclusion Criteria:\n\n1. Male or female patient who has received any type of chemotherapy treatment for cancer and are in remission.\n\n   Participants must be diagnosed with CIPN and must be showing moderate (Grade 2, as defined by the Common Terminology Criteria for Adverse Events) symptoms of peripheral sensory neuropathy, including pain and hypersensitivity, for ≥ 3 months. Participants must have had stable symptoms of CIPN for 8 weeks before screening. Participants with any other conditions associated with neuropathy, or conditions which might confound pain assessment (e.g. other severe pain or a skin condition in the area affected by neuropathy) will be excluded.\n2. Aged 18-80 years (inclusive) at the time of consent.\n3. Mean daily pain score of 4-8 on the 11-point NPRS, for at least 4 days during Run-in 1.\n4. A score of 0 or 1 on the ECOG Performance Status Scale.\n5. Capable of self-administering topical VMD-3866 or placebo gel to the designated treatment area(s).\n6. Capable of understanding the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.\n7. Agrees to take only the allowed rescue medication (paracetamol) for breakthrough pain, from screening and throughout the study.\n8. Willing to give written consent to participate after reading the informed consent form, and after having the opportunity to discuss the trial with the investigator or their delegate.\n9. Agrees to follow the contraception requirements of the trial.\n10. Agrees not to donate blood or blood products during the trial and for up to 3 months after the administration of the trial medication.\n\nExclusion Criteria:\n\n1. Woman who is pregnant or lactating, or premenopausal woman who is sexually active and not using a reliable method of contraception.\n2. History of painful conditions not associated with CIPN (e.g. frequent headache) that require administration of paracetamol or non-steroidal anti-inflammatory drugs, more than twice a week.\n3. Presence of peripheral neuropathy of another etiology (e.g. alcohol, diabetes, toxins, neurotoxic treatments, hereditary, autoimmune).\n4. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the participant.\n5. Clinical, history or previous laboratory evidence of significant conditions (e.g. diabetes, seizure or psychological conditions) that could interfere with completion of study procedures and assessments or pose an additional risk to the participant.\n6. Cardiovascular events (stroke, heart attack, pulmonary embolism) in the last 3 months.\n7. Significant psychiatric or neuropsychiatric disorders including but not limited to severe depression, dementia, bipolar disorder or schizophrenia spectrum disorder.\n8. History of suicide attempt, or suicidal ideation in the last 6 months.\n9. Presence of active and\u002For systemic infection, or history of severe infection during the 30 days prior to screening.\n10. Damaged or tattooed skin, active skin disease, infection, severe erythema, or any other compromise in integrity of skin at the designated treatment area(s), which could influence or interfere with the evaluation of the safety or efficacy of VMD-3866.\n11. Presence or history of severe adverse reaction(s) to any drug or a history of sensitivity to any excipients of VMD-3866.\n12. Participation in any studies for skin irritation or sensitization within the 30 days before first dose.\n13. If a skin biopsy is required: contraindications to skin biopsy (e.g. patients with significant bleeding tendencies or using anti-coagulants).\n14. Receipt of an investigational medicinal product (including prescription medicines and devices) as part of another clinical trial, in the 3 months before first dose or 5-half-lives (whichever is longer); or is in the follow-up period of another clinical trial at the time of screening for this trial.\n15. Use of topical capsaicin preparations (including Qutenza patch) in the 3 months before screening.\n16. Use of opiate medication within the 28 days before screening.\n17. Use of any pain medication (except the approved pain medications, see below), from 14 days before Run-in 1 to the last on-site study visit.\n\n    Non-approved medications include; salicylates, NSAIDs, topical analgesic-containing gels or creams or patches, local treatment with anesthetics (such as lidocaine), steroids, or transcutaneous electric nerve stimulation.\n\n    Approved medications include:\n    * medications for the treatment of CIPN; gabapentin, pregabalin, amitriptyline, duloxetine, or a combination of those. The same medication\u002Fcombination and dose should be used from 14 days before Run-in 1, until the end of the trial.\n    * paracetamol can be used as a rescue medication for pain as required.\n    * local anesthetic can be used prior to skin biopsy\n18. Scheduled to undergo radiation therapy or cancer chemotherapy during the trial.\n\n    Diagnostic\u002Fscreening assessments\n19. Blood pressure and pulse rate in supine position at the screening examination outside the following ranges: blood pressure 90-160 mm Hg systolic, 40-100 mm Hg diastolic; pulse rate 40\\_100 beats\u002Fmin. If the values are out of range, one repeat is permitted. Patients can be included if the repeat value is within range.\n20. QTcF \\> 450 msec (men) or \\> 470 msec (women) at Screening and pre-dose on Day 1. If the values are out of range, one repeat is permitted. Patients can be included if the repeat value is within range.\n21. Positive test for hepatitis B, hepatitis C or HIV.\n\n    Other\n22. Presence or history of drug or alcohol abuse within the last 10 years, intake of \\> 14 units of alcohol weekly, smoking \\> 10 cigarettes daily, or heavy use of e-cigarettes (including vapes).\n23. Evidence of drug abuse on urine testing.\n24. Completion of \\\u003C5 days in the 7-day Run-in 1 trial diary.\n25. Objection by GP, on medical grounds, to patient entering trial.\n26. Possibility that the patient will not cooperate with the requirements of the protocol.",{"count":490,"type":22},16,[492],"PHASE2","Peripheral neuropathy is a disorder caused by damage to the peripheral nerves. Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of certain chemotherapy drugs, such as platinum-based compounds, taxanes, and vinca alkaloids, which can damage nerve fibres by disrupting their structure and function. At present, relief of neuropathic pain in CIPN is limited, and existing therapies providing only modest and variable efficacy across patients.\n\nThis is a study of VMD-3866 gel (the study medicine which is non-opioid, non-NSAID), an experimental new topical medicine for treating pain caused by CIPN. The goal of this study is to assess if the study medicine improves pain symptoms in patients with CIPN, and to find out the side effects of the study medicine if any.\n\nThe study medicine will work by selectively blocking a specific sub-type of proteins (called T-type calcium channels) in the nerves under the skin which will lower the activity of the nerves and therefore reduce pain. It is a topical gel, meaning that it is applied to the skin, and its novel gel formulation limits that only little amount of study medicine may enter the blood and none enters the brain. This means it's unlikely to be addictive and it's unlikely to have any impact on participant current medications. Researchers will compare study medicine to a matching placebo (a look-alike gel that contains no drug) to see if VMD-3866 gel works to management of pain caused by CIPN.",[137,495],"Drug-Induced Nephropathy",[28,497,498,499,500,501,502,503,495],"Chemotherapy-Induced Peripheral Neuropathic Pain","Neuropathic Pain","Chronic Pain","Nephropathy","Tingling","Numbness","Burning","2026-03-23",{"date":193,"type":35},{"date":507,"type":35},"2025-12-12",{"date":509,"type":22},"2027-12-31",{"name":511,"class":512},"VM Therapeutics LLC","INDUSTRY",{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":522,"briefSummary":523,"conditions":524,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":534},"100421098","remote-monitoring-and-management-of-chemotherapy-induced-peripheral-neuropathy-100421098","NCT04763356","Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy","REMOTE-CIPN","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Age ≥ 18.\n2. Completion of taxane, platinum, vinca alkaloid-based chemotherapy, bortezomib, thalidomide, lenalidomide, ixazomib, or brentuximab vedotin for cancer in the last 540 days, or ongoing maintenance therapy with bortezomib, thalidomide, lenalidomide or ixazomib for \\> 90 days or ongoing survival, palliative or equivalent therapy with any of the above listed drugs for \\>90 days.\n3. Development of CIPN during or within 3 months of the most recently completed chemotherapy or previous neurotoxic chemotherapy for the same malignancy. For patients on ongoing maintenance therapy: Development of CIPN during current neurotoxic chemotherapy with bortezomib, thalidomide, lenalidomide, ixazomib brentuximab vendotin or vincristine. CIPN diagnosis will be based on clinical diagnosis and the Toronto Criteria for Probable Distal Symmetric Polyneuropathy including the upper and lower extremities.\n\n   The Toronto Criteria for Probable Distal Symmetric Polyneuropathy is defined as a combination of symptoms and signs of neuropathy including:\n   1. At least 1 (one) of the following neuropathic symptoms: \"asleep numbness\", prickling or stabbing, burning or aching pain AND\n   2. At least 1 (one) of the following: decreased distal sensation, or unequivocally decreased or absent ankle reflexes. (59)\n\n   Clinical Diagnosis:\n\n   a. Confirmation of CIPN diagnosis by CIPN expert (investigator\u002Fco-infestigator based on chart review +\u002F- inperson\u002Fvirtual interview with examination).\n4. Presence of at least one positive neuropathic sensory symptom on the NTSS-6 ranked as moderate or severe on the day of screening or in the preceding week based on recall.\n5. The ability to speak\u002F read sufficient English to be able to communicate with study NP over the phone, utilize the App, website and phone tree (all of which are only available in English).\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Expected treatment with another neurotoxic chemotherapy within the 13 week overall study duration (For example, platinum, taxane, vinca alkaloid, thalidomide, brentuximab vedotin or related drug, or arsenic trioxide. This exclusion does not apply to continuation of treatment for patients on maintenance therapy as described in the inclusion criteria).\n2. Presence of a neurological problem that would confound CIPN assessment (lumbar or cervical radiculopathy, or pre-existing neuropathy from another cause such as diabetes).\n3. Currently receiving treatment at a pain clinic specifically for CIPN pain.\n4. Concurrent participation in a different CIPN or pain treatment trial.\n5. For women of childbearing potential: Current pregnancy\n6. For women of childbearing potential: Unwillingness to use and acceptable form of birth control for the duration of the study. Acceptable forms of birth control include long acting implantable contraception (ie IUDs, Nexplanon), Oral contraception pills, contraception injections, or strict abstinence if it is part of the subject's current lifestyle.",{"count":521,"type":22},422,[25],"This is a prospective randomized trial designed to investigate a new care model for patients who suffer from nerve damage from chemotherapy called chemotherapy induced peripheral neuropathy (CIPN). All participants in the study will report their CIPN symptoms daily using a website, app or phone for 12 weeks. In one group the data will be collected and participants will be encouraged to reach out to their treating doctors for uncontrolled symptoms. These participants' doctors can prescribe any treatment they feel is appropriate. In the second group, if the symptoms meet the criteria for eligibility they will receive a phone call from a nurse practitioner either the same day or next day, depending on the time symptoms were logged. That nurse practitioner will determine the correct CIPN treatment using an algorithm and prescribe it. The study will track the severity of symptoms over time as well as looking at the impact on treatments for CIPN (medications and referrals).",[137],"2026-03-06",{"date":527,"type":35},"2026-03-10",{"date":529,"type":35},"2023-01-10",{"date":531,"type":22},"2026-09-30",{"name":533,"class":42},"University of Vermont",3,{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":224,"minAge":18,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":23,"phases":545,"briefSummary":546,"conditions":547,"keywords":550,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":559,"locationsCount":43},"100575190","the-use-of-acupuncture-to-reduce-chemotherapy-induced-peripheral-neuropathy-in-gynaecological-cancer-patients-100575190","NCT06769061","The Use of Acupuncture to Reduce Chemotherapy Induced Peripheral Neuropathy in Gynaecological Cancer Patients","The Use of Acupuncture to Reduce Chemotherapy Induced Peripheral Neuropathy (CIPN) in Gynaecological Cancer Patients - A Pilot Randomised Controlled Trial","AcuCIN","Inclusion Criteria:\n\n* Age 18 or above\n* Diagnosis of uterine (endometrial) cancer, ovarian cancer and cervical cancer\n* ECOG=0-2\n* Life expectancy of \\> 6 months\n* Completed at least 6 cycles of carboplatin or cisplatin chemotherapy together with paclitaxel at least 3 months before joining the study\n* Able to read and understand the questionnaires\n* PNQ score of C or above\n\nExclusion Criteria:\n\n* Bleeding tendency\n* Abnormal clotting profile\n* Platelet lower than 50\n* Received acupuncture in the past\n* Currently receiving chemotherapy treatment\n* Known neurological disorders or pre-existing neuropathy unrelated to chemotherapy\n* Routinely take aspirin or any anticoagulant drugs\n* Having active skin infection\n* With pacemaker",{"count":544,"type":22},75,[25],"Objectives:\n\nTo explore the feasibility and effectiveness of acupuncture on reducing Chemotherapy Induced Peripheral Neuropathy (CIPN) in gynaecological cancer patients who have received carboplatin and paclitaxel chemotherapy combination. Results of this pilot trial will provide preliminary information for a potential a larger scale multicentre study.\n\nHypothesis:\n\nAcupuncture can significantly reduce CIPN in gynaecological cancer patients treated with chemotherapy\n\nDesign and subjects:\n\nThis is a pilot, prospective randomised controlled trial. This is an exploratory trial to evaluate the feasibility and effectiveness of acupuncture in reducing CIPN in gynaecological cancer patients. Eligible patients will be 1:1:1 randomised to three groups: electroacupuncture group, sham acupuncture group and waiting-list (usual care) control group. For electroacupuncture and sham acupuncture groups, the assessors and the patients will be blinded to the treatment given.\n\n1. Electroacupuncture group - patients will receive 6 weeks of electroacupuncture, 2 sessions per week, by a qualified Traditional Chinese Medicine practitioner from the School of Chinese Medicine.\n2. Sham acupuncture group - patients will receive 6 weeks of sham acupuncture similar to the above.\n3. Waiting-list (usual care) control group - patients will not receive any treatment.\n\nMain outcomes:\n\nAcupuncture effects will be assessed at baseline and 3, 6,12 weeks post intervention by:\n\n1. Patient reported outcome measures: FACT\u002FGOG-Ntx questionnaire for assessing CIPN symptoms and EORTC-QLQ-C30 and CIPN20 questionnaires for assessing quality of life symptom\n2. Clinician reported outcome measures: NCI-CTCAE grading for CIPN by clinicians and Semmes-Weinstein monofilament test as an objective measurement of CIPN.\n\nData analysis:\n\nIntention to treat analysis will be carried out. Baseline demographics will be compared between the 3 groups. Change from baseline total score will be calculated and analysed using 2-sample t-test. 95% CI will be reported for treatment differences. Score for different subcategories will be analysed in a similar manner. Data collected at week 6 will be used for outcome analysis. P\\\u003C0.05 will be considered as statistically significant. Acupuncture efficacy, effectiveness and placebo effect will be indicated by comparison of acupuncture vs. sham acupuncture, acupuncture vs. waiting-list, and sham acupuncture vs. waiting-list, respectively.\n\nExpected results: Patients in the acupuncture arm will have reduced numbness and peripheral neuropathy and improved quality of life without any adverse event.",[548,28,549],"Gynaecological, Urological or Rectal Cancer","Acupuncture",[551,549,552],"Gynaecological Cancer","Chemotherapy induced peripheral neuropathy","2026-02-24",{"date":555,"type":35},"2026-02-25",{"date":557,"type":35},"2025-02-12",{"date":195,"type":22},{"name":560,"class":42},"Karen Kar Loen CHAN",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":567,"targetDuration":4,"studyType":23,"phases":569,"briefSummary":570,"conditions":571,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":579,"locationsCount":43},"100528563","exploring-the-benefit-of-peripheral-nerve-stimulation-in-treating-pain-from-chemo-induced-peripheral-neuropathy-a-longitudinal-single-center-feasibility-study-100528563","NCT06162403","Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study","Inclusion Criteria:\n\n* Participants diagnosed with chronic (≥90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds or ionizing irradiation) of the lower extremity, seen at Pain Management Center at MD Anderson Cancer Center\n* Participants reports baseline pain ≥ 4 (0-10 scale, NRS)\n* Participants between ages 18-85 years old\n* Participants who have completed chemotherapy within the previous year at the time of enrollment\n\nExclusion Criteria:\n\n* Participants with cognitive dysfunction\n* Participants with recent history (\\\u003C6 months) of drug or alcohol abuse\n* Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection\n* Participants with allergies to local anesthesia, steroids, or adhesives\n* Participants with conditions that conflict with the SPRINT PNS System Indications for Use, including Contraindications and Warnings.",{"count":568,"type":22},10,[25],"To learn if peripheral nerve stimulation (PNS) can help to improve pain in participants with CIPN.",[572,137],"Peripheral Nerve Stimulation","2026-02-17",{"date":575,"type":35},"2026-02-19",{"date":577,"type":35},"2024-02-22",{"date":509,"type":22},{"name":259,"class":42},{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":224,"minAge":18,"maxAge":75,"enrollmentInfo":587,"targetDuration":4,"studyType":23,"phases":588,"briefSummary":589,"conditions":590,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":43},"100606612","vgait-for-chemotherapy-induced-peripheral-neuropathy-100606612","NCT07177820","VGAIT for Chemotherapy-induced Peripheral Neuropathy","Video-Guided Acupuncture Imagery Treatment in Chemotherapy-induced Peripheral Neuropathy","Inclusion Criteria:\n\n* at least 18 years of age\n* have histologically confirmed stage I-III breast cancer,\n* have completed adjuvant taxane-based chemotherapy (alone or in combination), ,\n* have an Eastern Cooperative Oncology Group performance status of 0 or 1, and reported grade 1 or greater CIPN symptoms for more than 2 weeks as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.\n\nExclusion Criteria:\n\n* concurrent chemotherapy (there were no limitations on time from the last paclitaxel administration),\n* having metastatic or recurrent disease,\n* history of preexisting peripheral neuropathy prior to chemotherapy,\n* uncontrolled seizure disorder,\n* unstable cardiac disease or myocardial infarction within 6 months prior to study entry, being pregnant or nursing, or having used acupuncture for CIPN within 6 months prior to study entry.",{"count":157,"type":22},[25],"Perform a feasibility study on imagined acupuncture treatment of Chemotherapy-induced peripheral neuropathy (CIPN)",[137],"2026-02-06",{"date":593,"type":35},"2026-02-10",{"date":595,"type":35},"2026-01-06",{"date":597,"type":22},"2026-12-31",{"name":599,"class":42},"Massachusetts General Hospital"]